banner
 
bar

program

slides

  test

syllabus
bar
 
 

Cancer, Clotting and Controversies
Critical Challenges and Landmark Advances
in Venous Thromboembolism

Geneva, Switzerland

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Intended Audience:

The program is intended for thrombosis specialists, oncologists, hematologists, coagulation experts, cardiologists, surgeons, and related disciplines.

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

logoSupported by an independent
educational grant from
Eisai, Inc.

Accreditation Statement for Jointly-Sponsored Programs:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty and Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials

Faculty Disclosures:

Ajay Kakkar, MBBS, PhD, FRCS
Grants/research support: sanofi-aventis, AstraZeneca, Pfizer
Consultant: Pfizer, sanofi-aventis
Craig M. Kessler, MD
Grants/research support: sanofi-aventis, Eisai, GlaxoSmithKline, Octapharma
Consultant: sanofi-aventis, Eisai, NovoNordisk

Alex C. Spyropoulos, MD, FACP, FCCP
Grants/research support: sanofi-aventis, AstraZeneca
Consultant: sanofi-aventis, AstraZeneca

Samuel Z. Goldhaber, MD
Grant/Research Support: sanofi-aventis, GSK, Eisai

Program Faculty:

Program Chairman
Ajay Kakkar, MBBS, PhD, FRCS

Head of the Centre for Surgical Sciences
Barts and the London
Queen Mary's School of Medicine and Dentistry
Thrombosis Research Institute
London, UK

Distinguished Presenters
Craig M. Kessler, MD

Professor of Medicine and Pathology
Georgetown University Medical Center
Director of the Division of Coagulation
Department of Laboratory Medicine
Washington, DC

Alex C. Spyropoulos, MD, FACP, FCCP
Chair, Department of Clinical Thrombosis
Lovelace Medical Center
Clinical Associate Professor of Medicine
University of New Mexico
Albuquerque, New Mexico

Distinguished Panel Member, Consultant, and Visiting Professor
Samuel Z. Goldhaber, MD

Professor of Medicine, Cardiovascular Division
Harvard Medical School
Director, Venous Thromboembolism
Research Group
Director, Anticoagulation Service
Brigham and Women's Hospital
Boston, MA

Educational Objectives:

  • Clinicians will review recent trials, research, and expert analysis of issues focused on thrombosis and cancer.
  • Clinicians will specify strategies for risk-directed prophylaxis against DVT in at risk patients with cancer.
  • Clinicians will explain how to assess and manage special needs of cancer patients at risk for DVT, with a focus on protecting against recurrent DVT.
  • Clinicians will describe how to risk stratify patients undergoing cancer surgery, and implement ACCP-mandated pharmacologic and non-pharmacologic measures aimed at DVT prophylaxis.
  • Clinicians will review landmark clinical trials focusing on DVT prophylaxis in patients with cancer.
  • Clinicians will explain how to appropriately use the range of pharmacologic options available for thrombosis management in patients with malignancy.

Disclaimer:

Copyright © 2007 by Pharmatecture, LLC. All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this WebCAST reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this WebCAST is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this WebCAST is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This WebCAST is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This WebCAST is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

bar

program

slides

  test

syllabus
bar

YES, I have read the CME information statement

Copyright (c) 2007 All rights reserved


 
6

 

 

 

 

Key Program Topics Include:
ACCP Consensus Guidelines
Activation
Acute Illness
adhesive interactions
Akt
Angiogenesis
anticoagulants
Antithrombotic Therapy: Choices
ARISTOS
Armand Trousseau
ARTEMIS
Basement matrix
Bladder
Bleeding
Blood Coagulation
Brain
Breast
Cancer
Cancer Surgery
CANTHENOX
Central Venous Catheters
Cervix
Chemotherapy
CLOT
Clotting
Clotting dependent
Clotting independent
Coagulation
Colon










Dalteparin
Direct anti-IIa
Direct anti-Xa inhibitors
Distant
DVT
Eisai
Elastic Stockings
Endothelial
Endothelial cells
ENOXACAN
Enoxaparin
Esophagus
ETHICS
FAME
FIBRIN
Fibrinolytic
FRONTLINE
FVII/FVIIa
Gastrointestinal
Glioblastoma
Hematological
HIT
Hospitalization
Hypercoagulability
Hypoxia
IL-1
IL-8
immobilization
Inferior Vena Cava Filter
Kidney
Leukemia
Liver
LMWH

Low Molecular Weight Heparin
Lung
Lymphoma
Malignancy
MALT
MEDENOX
medical illness (22%)
MET
metastases
Monocyte
Myeloma
Myeloprol
Nadroparin
ONCENOX
oncogene
Oncology
Ovary
PAI-1
PAI-2
Pancreas
PAR-2
Pathogenesis
Pentasaccharide
Platelets
PMN leukocyte
Pneumatic Compression
PREVENT
Procoagulant Activities
Prophylaxis
Prostate
Protease




Pseudopalisading
Pten
Radiotherapy
Ras
Rectal
SCLC
selectin/integrin-mediated
solid tumour malignancy
Stasis
Stomach
Surgery
TF
TF si mRNA
thrombohemorrhagic syndrome
thromboprophylaxis.
Thrombosis
Tinzaparin
TNF-α,
t-PA
Tumor cells
u-PA
u-PAR
Uterus
Vascular Injury
VEGF
VEGF
Venous thromboembolism
Virchow’s Triad
VTE
VTE in Hospitalized Cancer
Warfarin